Product Name:
PKC-III (PKCa-1)
Product Number:
ab-nk201
Target Full Name: Protein-serine kinase C alpha
Target Alias: AAG6; Kinase PKC-alpha; KPCA; PKC III; PKC-A; PKC-alpha; PKC-III; PRKACA; Protein kinase C, alpha; Protein kinase C, alpha type; MGC129900; MGC129901; CCDS11664.1; P17252; ENSG00000154229
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK201
Antibody Target Type: Pan-specific
Protein UniProt: P17252
Protein SigNET: P17252
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human PKCa (PRKCA) sequence peptide
Antibody Immunogen Sequence: KKDVVIQDDDVESTMVEKC
Antibody Immunogen Description: Corresponds to amino acid residues K371 to K388; Kinase catalytic subdomain 3
Production Method: Corresponds to amino acid residues K371 to K388; Kinase catalytic subdomain 3
Antibody Modification: Protein kinase pan-specific antibody
Antibody Concentration: 0.5 mg/ml
Storage Buffer: 100 mM Tris-glycine, pH 7.0
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months, but either 0.1% sodium azide or 0.05% Thimerasol should be added. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human; Mouse; Rat; Cow
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 75-90 kDa.
Antibody Cross Reactivity: This antibody will cross-react with the alpha, beta and gamma isoforms of protein kinase C.
Related Product 1: PKCa-pT497 phosphosite-specific antibody (Cat. No.: AB-PK763)
Related Product 2: PKCa-pY195 phosphosite-specific antibody (Cat. No.: AB-PK764)
Related Product 3: CREB1 (123-135) KinSub - cyclic-AMP response element binding protein-1 (K123-R135, human) peptide; Crebtide protein kinase substrate peptide
Related Product 4: CREB1 (123-135) KinSub, biotinyl. - cyclic-AMP response element binding protein-1 (K123-R135, human) peptide; Crebtide protein kinase substrate peptide
Related Product 5: PKCA/BSubtide - PKCa (PRKCA) protein kinase substrate peptide
Related Product 6: PKCtide KinSub - Protein kinase C peptide substrate
Related Product 7: Syntide-2 KinSub - Syntide-2 protein kinase substrate peptide
Scientific Background: PKCa (PRKCA, PKC-alpha) is a protein-serine/threonine kinase in the classical protein kinase C family. This kinase is moderate to highly expressed in most tested human tissues. It is calcium activated, and dependent on acidic phospholipids (e.g. phosphatidylserine) and diacylglycerol for full phosphotransferase activity. Fatty acids can also activate PKCa. Phosphorylation of T494, T495 and T497 increases kinase activity. Phosphorylation of S657 increases phosphotransferase activity, protects against dephosphorylation of the T497 site and degradation of PKC-alpha. Phosphorylation of T638 is not essential for catalytic activity, but it protects against dephosphorylation of the T497 site. PKCa has been identified as a fundamental regulator of cardiac contractility and Ca(2+) handling in myocytes. PKCa has been linked with the development of colon, pituitary and thyroid cancers as well as glioblastoma multiforme (GM). PKCa has been considered as an oncoprotein (OP), since during tumourigenesis, as it is strongly activated by many different tumour promoting compounds, such as phorbol esters and teleocidins. While these compounds promote binding of PKC isoforms to the plasma membrane of cells, which stimulates their phosphotransferase activity, these agents also induce rapid down-regulation of PKC isoforms. Consequently, PKCa may be actually be a tumour suppressor protein. PKCa is highly expressed in several cancers, including malignant breast cancers and gliomas. Increased expression of PKCa has been observed in adenomatous pituitaries, with highest expression in invasive pituitary tumours. A point mutation was also identified in 4 invasive pituitary tumours. Furthermore, PKCa appears to stimulate cell proliferation, because many of its direct targets, such as Raf1, Bcl2, and CSPG4, participate in growth factor signalling pathways and PKC activators induce the downstream activation of ERK1/2 (MAPK3/1) and RAP1-GAP.
